Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?-Reference-Cited by-同舟云学术

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?

Published:2018-04-04 Issue:8 Volume:89 Page:844-850
ISSN:0022-3050
Container-title:Journal of Neurology, Neurosurgery & Psychiatry
language:en
Short-container-title:J Neurol Neurosurg Psychiatry

Author:

Cerqueira João J^ORCID,Compston D Alastair S,Geraldes Ruth,Rosa Mario M,Schmierer Klaus,Thompson Alan,Tinelli Michela,Palace Jacqueline

Funder

F. Hoffmann-La Roche

Publisher

BMJ

Subject

Psychiatry and Mental health,Neurology (clinical),Surgery

Reference104 articles.

1. Disease modifying therapies for relapsing multiple sclerosis

2. The changing face of multiple sclerosis: Prevalence and incidence in an aging population

3. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study

4. Comorbidity in multiple sclerosis: implications for patient care;Marrie;Nat Rev Neurol,2017

5. Cortical demyelination and diffuse white matter injury in multiple sclerosis

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis;Multiple Sclerosis and Related Disorders;2024-07

2. Impact of Genetic Polymorphisms in the Interleukin-18 and Interleukin-21 Genes on the Risk and Clinical Outcomes of Multiple Sclerosis;2024-06-06

3. miR-24-3p and miR-484 are potential biomarkers for neurodegeneration in multiple sclerosis;Heliyon;2024-06

4. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption;Journal of Neurology;2024-04-14

5. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab;JAMA Network Open;2024-04-12